• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Spesolimab use in treatment of pyoderma gangrenosum.

作者信息

Guénin Sophie H, Khattri Saakshi, Lebwohl Mark G

机构信息

The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York.

出版信息

JAAD Case Rep. 2023 Feb 4;34:18-22. doi: 10.1016/j.jdcr.2023.01.022. eCollection 2023 Apr.

DOI:10.1016/j.jdcr.2023.01.022
PMID:36936866
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10015112/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22c/10015112/a4c25429d870/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22c/10015112/1ecd2d6c97ef/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22c/10015112/298d6f8e2b3f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22c/10015112/a4c25429d870/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22c/10015112/1ecd2d6c97ef/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22c/10015112/298d6f8e2b3f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22c/10015112/a4c25429d870/gr3.jpg

相似文献

1
Spesolimab use in treatment of pyoderma gangrenosum.司妥昔单抗用于坏疽性脓皮病的治疗。
JAAD Case Rep. 2023 Feb 4;34:18-22. doi: 10.1016/j.jdcr.2023.01.022. eCollection 2023 Apr.
2
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.Effisayil™ 2的设计：一项关于司帕索利单抗预防泛发性脓疱型银屑病患者病情发作的随机、双盲、安慰剂对照研究。
Dermatol Ther (Heidelb). 2023 Jan;13(1):347-359. doi: 10.1007/s13555-022-00835-6. Epub 2022 Nov 5.
3
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.脓疱型银屑病：全身性脓疱型银屑病中 spesolimab 的分子途径和作用。
J Allergy Clin Immunol. 2022 Apr;149(4):1402-1412. doi: 10.1016/j.jaci.2021.09.035. Epub 2021 Oct 20.
4
Development of pemphigus vegetans and exacerbation of pemphigus foliaceus after secukinumab loading in a patient with complicated generalized pustular psoriasis and pyoderma gangrenosum.司库奇尤单抗负荷剂量治疗一名合并泛发性脓疱型银屑病和坏疽性脓皮病患者后，出现增殖性天疱疮并加重落叶型天疱疮。
J Dermatol. 2023 Feb;50(2):245-249. doi: 10.1111/1346-8138.16563. Epub 2022 Sep 2.
5
Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis.斯佩索利单抗：首款获批用于泛发性脓疱型银屑病的白细胞介素-36阻滞剂综述
Ann Pharmacother. 2025 Feb;59(2):174-183. doi: 10.1177/10600280241252688. Epub 2024 May 16.
6
Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis.关于人源化抗白细胞介素-36受体单克隆抗体斯佩索利单抗治疗泛发性脓疱型银屑病的一项临床试验的评论
Dermatol Ther (Heidelb). 2022 Dec;12(12):2627-2635. doi: 10.1007/s13555-022-00830-x. Epub 2022 Oct 8.
7
Trial of Spesolimab for Generalized Pustular Psoriasis.特索利单抗治疗泛发性脓疱型银屑病的试验。
N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563.
8
Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab.患有杂合性低功能MPO变异的泛发性脓疱型银屑病患者，对静脉注射司帕利单抗难治。
J Dermatol. 2025 Jan;52(1):167-170. doi: 10.1111/1346-8138.17464. Epub 2024 Sep 20.
9
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.全球 Effisayil 1 期 II 期、多中心、随机、双盲、安慰剂对照研究方案，评估 spesolimab 在伴有急性发作的泛发性脓疱性银屑病患者中的疗效。
BMJ Open. 2021 Mar 30;11(3):e043666. doi: 10.1136/bmjopen-2020-043666.
10
Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study.斯帕斯利单抗改善泛发性脓疱型银屑病患者的患者报告结局：Effisayil 1 研究结果。
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):730-736. doi: 10.1111/jdv.18820. Epub 2023 Jan 23.

引用本文的文献

1
Enhanced Innate Immunity Mediated by IL-36α in Atopic Dermatitis and Differences in Cytokine Profiles of Lymphocytes in the Skin and Draining Lymph Nodes.IL-36α介导的特应性皮炎中固有免疫增强及皮肤和引流淋巴结中淋巴细胞细胞因子谱的差异
Biomolecules. 2025 Jun 4;15(6):817. doi: 10.3390/biom15060817.
2
Case Report: Spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy.病例报告：司妥昔单抗用于一名接受抗IL-17治疗的未分化寡关节炎患者的坏疽性脓皮病
Front Immunol. 2025 Apr 7;16:1581996. doi: 10.3389/fimmu.2025.1581996. eCollection 2025.
3
Case report: A rollercoaster journey of pemphigus vegetans.

本文引用的文献

1
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study.使用德尔菲法和帕拉塞尔苏斯标准评估组织病理学在坏疽性脓皮病诊断中的作用：一项多中心回顾性队列研究。
Br J Dermatol. 2022 Jun;186(6):1035-1037. doi: 10.1111/bjd.20967. Epub 2022 Mar 16.
2
Trial of Spesolimab for Generalized Pustular Psoriasis.特索利单抗治疗泛发性脓疱型银屑病的试验。
N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563.
3
Biology of IL-36 Signaling and Its Role in Systemic Inflammatory Diseases.
病例报告：增殖性天疱疮的一段跌宕起伏历程。
Front Immunol. 2025 Jan 13;15:1481192. doi: 10.3389/fimmu.2024.1481192. eCollection 2024.
4
Anti-IL 17 biologics and pyoderma gangrenosum - therapeutic or causal?抗白细胞介素17生物制剂与坏疽性脓皮病——治疗作用还是因果关系？
Arch Dermatol Res. 2025 Jan 13;317(1):235. doi: 10.1007/s00403-024-03689-4.
5
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases.指导炎症性皮肤病诊断和个性化治疗的免疫模块。
Nat Commun. 2024 Dec 18;15(1):10688. doi: 10.1038/s41467-024-54559-6.
6
Effective Management of Life-Threatening Generalized Pustular Psoriasis Flare With Spesolimab.使用司库奇尤单抗有效管理危及生命的泛发性脓疱型银屑病发作
Cureus. 2024 Jul 13;16(7):e64474. doi: 10.7759/cureus.64474. eCollection 2024 Jul.
7
Generalized pustular psoriasis successfully treated with spesolimab: A case report.司库奇尤单抗成功治疗泛发性脓疱型银屑病：一例报告
SAGE Open Med Case Rep. 2024 Feb 27;12:2050313X241235451. doi: 10.1177/2050313X241235451. eCollection 2024.
8
The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives.坏疽性脓皮病的发病机制和治疗：现有选择和新视角。
Int J Mol Sci. 2024 Feb 19;25(4):2440. doi: 10.3390/ijms25042440.
9
Genetic mutations in pyoderma gangrenosum, hidradenitis suppurativa, and associated autoinflammatory syndromes: Insights into pathogenic mechanisms and shared pathways.化脓性汗腺炎、聚合性痤疮和相关自身炎症性综合征的遗传突变：对发病机制和共同途径的深入了解。
J Dermatol. 2024 Feb;51(2):160-171. doi: 10.1111/1346-8138.17028. Epub 2023 Nov 30.
IL-36 信号的生物学及其在系统性炎症性疾病中的作用。
Front Immunol. 2019 Oct 31;10:2532. doi: 10.3389/fimmu.2019.02532. eCollection 2019.
4
Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis.美国坏疽性脓皮病的流行率估计：年龄和性别调整后的人群分析。
J Am Acad Dermatol. 2020 Aug;83(2):425-429. doi: 10.1016/j.jaad.2019.08.001. Epub 2019 Aug 7.
5
Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment.坏疽性脓皮病：病理生理学、诊断和治疗的最新进展。
Am J Clin Dermatol. 2017 Jun;18(3):355-372. doi: 10.1007/s40257-017-0251-7.
6
Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines.中性粒细胞衍生蛋白酶通过激活白细胞介素 36 家族细胞因子加重炎症反应。
Cell Rep. 2016 Feb 2;14(4):708-722. doi: 10.1016/j.celrep.2015.12.072. Epub 2016 Jan 14.
7
Canakinumab in adults with steroid-refractory pyoderma gangrenosum.卡那奴单抗治疗类固醇难治性坏疽性脓皮病的成人患者。
Br J Dermatol. 2015 Nov;173(5):1216-23. doi: 10.1111/bjd.14037. Epub 2015 Oct 16.
8
Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis.体外和体内 Th17 细胞因子与 IL-36 细胞因子的相互调节：对银屑病发病机制的影响。
J Invest Dermatol. 2011 Dec;131(12):2428-37. doi: 10.1038/jid.2011.234. Epub 2011 Sep 1.
9
Adalimumab for treatment of pyoderma gangrenosum.阿达木单抗治疗坏疽性脓皮病。
Br J Dermatol. 2007 Dec;157(6):1274-5. doi: 10.1111/j.1365-2133.2007.08212.x. Epub 2007 Oct 4.
10
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.英夫利昔单抗治疗坏疽性脓皮病：一项随机、双盲、安慰剂对照试验。
Gut. 2006 Apr;55(4):505-9. doi: 10.1136/gut.2005.074815. Epub 2005 Sep 27.